RTTNews | May 24, 2021 07:36AM EDT

07:35 Monday, May 24, 2021 (RTTNews.com) - Genetic testing and precision medicine company Myriad Genetics, Inc. (MYGN) announced Monday it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA Holdings, Inc. (IQV). The terms of the deal were not disclosed.

Q2 Solutions provides comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions.

Myriad RBM, which specializes in contract research services for the pharmaceutical industry, will be added to the overall Q2 Solutions menu and offerings.

The divestiture of Myriad RBM, along with other announced divestitures, allows Myriad Genetics to accelerate the execution of their transformation plan and focus on advancing their core businesses in Women's Health, Oncology and Mental Health.

The deal is subject to customary closing conditions, and Myriad expects the transaction to close in the third calendar quarter.

Read the original article on RTTNews ( https://www.rttnews.com/3196953/myriad-genetics-to-sell-myriad-rbm-to-q2-solutions-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved